Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
20 hedge funds and large institutions have $129M invested in Astria Therapeutics in 2015 Q2 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
68.76% more ownership
Funds ownership: 0% → 68.76% (+69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHI
SV Health Investors
Boston,
Massachusetts
|
+$36M |
| 2 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
+$34.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.3M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$11.7M |
| 5 |
DM
Deerfield Management
New York
|
+$9.3M |
Top Sellers
ATXS Hedge Fund Activity: Q2 2015 in Review
20 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2015, worth a combined $129M.
Buyers outnumbered sellers: 20 funds opened new ATXS positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SV Health Investors, opening a new position worth an estimated $36M.
- 20 institutional investors held Astria Therapeutics (ATXS) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $129M of Astria Therapeutics stock for Q2 2015.
- 20 funds opened new Astria Therapeutics positions in Q2 2015 and 0 closed out, a net change of +20 holders.
- The largest Astria Therapeutics buyer in Q2 2015 was SV Health Investors, an estimated $36M added.
Based on aggregated 13F filings for Q2 2015.